Prognostic Value of Pretreatment Lymphocyte-to-monocyte Ratio in Patients with Urologic Tumors: A PRISMA-compliant Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Jan 12

PMID 30633220

Citations 7

Authors

Jialin Li

Yusheng Cheng

Zhigang Ji

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value of pretreatment lymphocyte to monocyte ratio (LMR) in patients with urologic tumors remains controversial. Therefore, we herein conducted a meta-analysis to systematically assess the prognostic value of LMR in patients with urologic tumors.

Methods: We comprehensively searched PubMed, EMBASE and Web of Science to identify eligible studies. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to assess the prognostic value of LMR in patients with urologic tumors. This meta-analysis was registered in PROSPERO (CRD42018108959).

Results: A total of 20 studies were included in this meta-analysis. Our synthesized analysis showed that low LMR was significantly correlated with poor overall survival (OS) and progression-free survival (PFS) in patients with upper tract urothelial cancer (UTUC). We also found that renal cell cancer (RCC) patients with low LMR had poor OS, PFS and cancer-specific survival (CSS). Besides, it was observed that low LMR predicted poor OS, RFS and CSS in patients with bladder cancer (BC).

Conclusion: This meta-analysis demonstrated that pretreatment LMR is associated with survival, and may be a useful prognostic parameter in urologic tumors. Nevertheless, more prospective and heterogeneous studies with large samples are required to further confirm our findings before it is applied for daily clinical decision making.

Citing Articles

Pretreatment systemic immune-inflammation index and lymphocyte-to-monocyte ratio as prognostic factors in oral cavity cancer: A meta-analysis.

Xu J, Lin Y, Yang J, Xing Y, Xing X Medicine (Baltimore). 2024; 103(44):e40182.

PMID: 39496022 PMC: 11537607. DOI: 10.1097/MD.0000000000040182.

The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.

Numakura K, Sekine Y, Osawa T, Naito S, Tokairin O, Muto Y Int J Clin Oncol. 2024; 29(7):1019-1026.

PMID: 38797782 DOI: 10.1007/s10147-024-02538-8.

Inflammatory Markers and Thromboembolic Risk in Patients with Non-Muscle-Invasive Bladder Cancer.

Balan D, Vartolomei M, Magdas A, Balan-Bernstein N, Voidazan S, Martha O J Clin Med. 2021; 10(22).

PMID: 34830552 PMC: 8617657. DOI: 10.3390/jcm10225270.

Prognostic Impact of Monocyte to Lymphocyte Ratio in Clinical Outcome of Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Nouri-Vaskeh M, Mirza-Aghazadeh-Attari M, Pashazadeh F, Azami-Aghdash S, Alizadeh H, Pouya P Galen Med J. 2021; 9:e1948.

PMID: 34466618 PMC: 8344106. DOI: 10.31661/gmj.v9i0.1948.

Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer.

Adamkiewicz M, Bryniarski P, Kowalik M, Burzynski B, Rajwa P, Paradysz A Front Oncol. 2021; 11:655000.

PMID: 33842371 PMC: 8033152. DOI: 10.3389/fonc.2021.655000.

References

Rajwa P, Zyczkowski M, Paradysz A, Bujak K, Bryniarski P . Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci. 2018; 22(10):3027-3037. DOI: 10.26355/eurrev_201805_15060. View

Knobloch K, Yoon U, Vogt P . Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2010; 39(2):91-2. DOI: 10.1016/j.jcms.2010.11.001. View

Chang Y, Fu Q, Xu L, Zhou L, Liu Z, Yang Y . Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma. Tumour Biol. 2015; 37(4):4613-20. DOI: 10.1007/s13277-015-4300-7. View

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

Gu L, Ma X, Xie Y, Li H, Wang L, Chen L . Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2017; 15(3):e369-e377. DOI: 10.1016/j.clgc.2016.12.001. View

Xia W, Wu X, Yu T, Wu Y, Yao X, Hu H . Prognostic significance of lymphocyte-to-monocyte ratio and CRP in patients with nonmetastatic clear cell renal cell carcinoma: a retrospective multicenter analysis. Onco Targets Ther. 2016; 9:2759-67. PMC: 4869664. DOI: 10.2147/OTT.S101458. View

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

Hutterer G, Sobolev N, Ehrlich G, Gutschi T, Stojakovic T, Mannweiler S . Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma. J Clin Pathol. 2015; 68(5):351-5. DOI: 10.1136/jclinpath-2014-202658. View

Lieto E, Galizia G, Auricchio A, Cardella F, Mabilia A, Basile N . Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. J Gastrointest Surg. 2017; 21(11):1764-1774. DOI: 10.1007/s11605-017-3515-x. View

10.

Crusz S, Balkwill F . Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015; 12(10):584-96. DOI: 10.1038/nrclinonc.2015.105. View

11.

Vartolomei M, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B . Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. Urol Oncol. 2018; 36(9):389-399. DOI: 10.1016/j.urolonc.2018.05.014. View

12.

Hu G, Liu G, Ma J, Hu R . Lymphocyte-to-monocyte ratio in esophageal squamous cell carcinoma prognosis. Clin Chim Acta. 2018; 486:44-48. DOI: 10.1016/j.cca.2018.07.029. View

13.

Failing J, Yan Y, Porrata L, Markovic S . Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients. Melanoma Res. 2017; 27(6):596-600. DOI: 10.1097/CMR.0000000000000404. View

14.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

15.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

16.

Lucca I, de Martino M, Hofbauer S, Zamani N, Shariat S, Klatte T . Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. World J Urol. 2015; 33(12):2045-52. DOI: 10.1007/s00345-015-1559-7. View

17.

Temraz S, Mukherji D, Farhat Z, Nasr R, Charafeddine M, Shahait M . Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol. 2014; 14:76. PMC: 4171398. DOI: 10.1186/1471-2490-14-76. View

18.

Laughter A, TWOMEY J . Suppression of lymphoproliferation by high concentrations of normal human mononuclear leukocytes. J Immunol. 1977; 119(1):173-9. View

19.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

20.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View